丁二磺酸腺苷蛋氨酸辅助治疗原发性胆汁性胆管炎的临床疗效观察

肝脏 ›› 2021, Vol. 26 ›› Issue (6): 661-663.

丁二磺酸腺苷蛋氨酸辅助治疗原发性胆汁性胆管炎的临床疗效观察

杜晓菲, 陈杰, 任姗, 张小丹, 黄春洋, 单晶

100069 北京首都医科大学附属北京佑安医院肝病免疫科

收稿日期:2021-01-17 出版日期:2021-06-30 发布日期:2021-07-19
通讯作者: 单晶,Email:yayygbmyk@sina.com
基金资助:
北京市属医院科研培育计划项目(PX2019062)

Effect of S-adenosyl-L-methionine in patients with primary biliary cholangitis treated with ursodeoxycholic acid

DU Xiao-fei, CHEN Jie, REN Shan, ZHANG Xiao-dan, HUANG Chun-yang, SHAN Jing

Department of Immunopathy and Hepatology, Beijing Youan Hospital, Capital Medical University,Beijing 100069, China

Received:2021-01-17 Online:2021-06-30 Published:2021-07-19
Contact: SHAN Jing,Email:yayygbmyk@sina.com

摘要/Abstract

摘要： 目的观察丁二磺酸腺苷蛋氨酸辅助治疗原发性胆汁性胆管炎临床疗效。方法选取2018年1月至2019年12月原发性胆汁性胆管炎初治患者50例,随机分2组,对照组予熊去氧胆酸治疗,观察组予熊去氧胆酸联合丁二磺酸腺苷蛋氨酸治疗,丁二磺酸腺苷蛋氨酸静脉注射两周后改口服治疗,总疗程24周。治疗前及治疗6个月、1年时检测肝功能和肝脏弹性。结果治疗6个月爱媛标准判断疗效,观察组应答为23例(92.0%),显著高于对照组17(68.0%),差异有统计学意义(P=0.034);治疗1年巴塞罗那标准判断疗效,观察组应答为20例(80.0%),高于对照组17(68.0%),但差异无统计学意义(P=0.333),治疗后6个月和1年,观察组肝弹性测定值为[(6.6±2.5)kPa,(6.8±3.0)kPa],低于对照组[(6.8±3.0)kPa,(7.4±2.7)kPa],但差异无统计学意义。两组均无严重不良反应。结论丁二磺酸腺苷蛋氨酸辅助治疗原发性胆汁性胆管炎近期临床效果显著。

关键词: 丁二磺酸腺苷蛋氨酸, 原发性胆汁性胆管炎, 疗效

Abstract: Objective To investigate the effect of S-Adenosyl-L-Methionine (SAMe) supplementation on liver biochemistry and liver stiffness measurement (LSM) value in patients with primary biliary cholangitis (PBC), treated with Ursodeoxycholic acid (UDCA).Methods The all 50 patients with PBC were enrolled and divided into two groups randomly and averagely. They had received UDCA treatment. The patients in observation group additionally had been treated with SAMe in the dose of 1000 mg daily over a period of 24 weeks. SAMe had been injected intravenously for two weeks and then orally treated. Liver function and LSM were measured before treatment, 6 months after treatment and 1 year after treatment.Results The therapeutic effect was judged by Ehime standard after 6 months’ treatment. There were 23 cases had response in observation group (92.0%), significantly higher than that in the control group (17 cases, 68.0%, P=0.034). The therapeutic effect was judged by Barcelona standard after 1 year treatment. There were 20 cases had response in the treatment group (80.0%), which was higher than that in the control group (17 cases, 68.0%), but the difference was not statistically significant (P=0.333). 6 months and 1 year after treatment, LSM value in observation group was [(6.6±2.5)kPa, (6.8±3.0) kPa], which was lower than that in control group [(6.8±3.0)kPa, (7.4±2.7) kPa], but the difference was not statistically significant as well. There were no serious adverse reactions in both groups.Conclusion Our study demonstrates a positive effect of adding SAMe to UDCA in patients with PBC in near future.

Key words: S-Adenosyl-L-Methionine, Primary biliary cholangitis, Effect

杜晓菲, 陈杰, 任姗, 张小丹, 黄春洋, 单晶. 丁二磺酸腺苷蛋氨酸辅助治疗原发性胆汁性胆管炎的临床疗效观察[J]. 肝脏, 2021, 26(6): 661-663.

DU Xiao-fei, CHEN Jie, REN Shan, ZHANG Xiao-dan, HUANG Chun-yang, SHAN Jing. Effect of S-adenosyl-L-methionine in patients with primary biliary cholangitis treated with ursodeoxycholic acid[J]. Chinese Hepatolgy, 2021, 26(6): 661-663.

参考文献

[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017,67:145-172.
[2] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015).中华传染病杂志,2016,34:385-394.
[3] Guo T, Chang L, Xiao Y, et al. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One. 2015,10:e0122124.
[4] Wunsch E, Raszeja-Wyszomirska J, Barbier O, et al. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis, 2018,27:273-279.
[5] Kilanczyk E, Banales JM, Wunsch E, et al. S-adenosyl-L-methionine (SAMe) halts the autoimmune response in patients with primary biliary cholangitis (PBC) via antioxidant and S-glutathionylation processes in cholangiocytes. Biochim Biophys Acta Mol Basis Dis, 2020,1866:165895.
[6] Azemoto N, Abe M, Murata Y, et al. Earlybiochemicalresponse to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol, 2009,44:630-634.
[7] Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology, 2006,130:715-720.
[8] 边新渠,陈杰,刘燕敏,等.熊去氧胆酸治疗原发性胆汁性胆管炎患者血清甲状腺激素水平变化.实用肝脏病杂志,2019,22:716-719.
[9] 陈杰,黄春洋,黄云丽,等.大黄利胆胶囊对熊去氧胆酸经治的原发性胆汁性胆管炎患者临床疗效观察.中西医结合肝病杂志,2020,30:492-494.
[10] 王建军,赵平. S-腺苷蛋氨酸临床应用研究进展.2011,3:57-60.
[11] 郝娟,吕靖,邢枫,等.原发性胆汁性胆管炎的药物治疗进展.临床肝胆病杂志,2020,36:222-226.
[12] Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol, 2012,57:1097-1109.

[1]	冯倩嫦, 张春兰, 李凌华, 张健珍, 许敏, 蔡卫平. 索磷布韦维帕他韦治疗慢性丙型肝炎的真实世界研究[J]. 肝脏, 2021, 26(6): 606-610.
[2]	王闯胜, 孙婕, 石佳. 水隔离技术用于原发性肝癌MWA治疗对患者3年预后的影响[J]. 肝脏, 2021, 26(5): 527-529.
[3]	田晓玲, 陈莉, 鲁应佳, 何瑶. 泼尼松缓慢减量在自身免疫性肝炎治疗中的临床应用效果比较[J]. 肝脏, 2021, 26(5): 547-549.
[4]	汪玉龙, 郝维敏, 郭志国, 王晶, 刘志. 原发性胆汁性胆管炎患者PBMC中Caspase-1与IL-18水平观察[J]. 肝脏, 2021, 26(4): 421-423.
[5]	李贲, 纪世博, 赵莹莹, 程丹颖, 李炜, 欧蔚妮, 邢卉春. 双环醇治疗非酒精性脂肪性肝病疗效的meta分析[J]. 肝脏, 2021, 26(4): 424-428.
[6]	李丛辉, 罗红缨, 王建钧, 邝学军, 鲍永慧. 超声造影联合血γ-GT水平在原发性肝癌患者TACE术后疗效评估中的价值[J]. 肝脏, 2021, 26(3): 266-269.
[7]	贲友凤, 顾融融, 袁伯稳. 布拉酵母菌联合白蛋白及LED蓝光间歇照射治疗新生儿高胆红素血症的效果[J]. 肝脏, 2021, 26(3): 318-320.
[8]	段瑞芳, 杨道坤, 魏帅. TACE联合阿帕替尼治疗中晚期肝癌临床疗效与安全性的meta分析[J]. 肝脏, 2021, 26(1): 55-59.
[9]	李爱敏, 曹斌. 原发性胆汁性胆管炎患者病理分期与生化指标的相关性分析[J]. 肝脏, 2021, 26(1): 81-83.
[10]	张梅芹, 沈兰超, 陈国峰, 吕春. 自身免疫性肝炎与原发性胆汁性胆管炎重叠综合征患者的临床病理学特征分析[J]. 肝脏, 2020, 25(9): 965-967.
[11]	王家欢, 李震. ¹²⁵I放射粒子植入联合肝动脉栓塞术对原发性肝癌的疗效及对肝脏TRF1和TRF2表达影响[J]. 肝脏, 2020, 25(4): 402-406.
[12]	周西, 刘启榆, 杨伟, 王忠, 范丹丹, 温凌字. CT能谱成像与MRI在肝细胞癌TACE术后疗效评估中的对比研究[J]. 肝脏, 2020, 25(4): 409-412.
[13]	郭萍, 袁志平. 三维适形放疗联合TACE治疗中晚期肝癌患者的早期疗效[J]. 肝脏, 2020, 25(12): 1269-1271.
[14]	张伟华, 秦艳青, 沈金杰. IRE联合NK细胞治疗原发性肝癌的安全性和临床疗效[J]. 肝脏, 2020, 25(12): 1272-1274.
[15]	王晶, 江振宇, 张静洁, 苏日古格, 苏琪浩, 党彤, 孟宪梅, 贾燕. 原发性胆汁性胆管炎患者的生存质量现状及临床结局[J]. 肝脏, 2020, 25(11): 1220-1222.